Oliver Leismann

Results from a 1-year, open-label, single arm, multi-center trial evaluating the efficacy and safety of oral Deferasirox in patients diagnosed with low and int-1 risk myelodysplastic syndrome (MDS) and transfusion-dependent iron overload

Florian Nolte, Britta Höchsmann, Aristoteles Giagounidis et al. · Annals of Hematology · 2012 · 78 citations

Medicine, Pharmacology, Pharmacotherapy +16

Deferasirox in MDS patients with transfusion-caused iron overload—a phase-II study

Georgia Metzgeroth, Dietmar Dinter, Beate Schultheis et al. · Annals of Hematology · 2008 · 60 citations · Full text

Medicine, Hematology, Internal Medicine +15

Deferasirox treatment of iron‐overloaded chelation‐naïve and prechelated patients with myelodysplastic syndromes in medical practice: results from the observational studies eXtend and eXjange

Norbert Gattermann, Andrea Jarisch, Rudolf Schlag et al. · European Journal Of Haematology · 2011 · 38 citations · Full text

Medicine, Hematology, Pharmacotherapy +17

Efficacy and safety of deferasirox in non-thalassemic patients with elevated ferritin levels after allogeneic hematopoietic stem cell transplantation

Nadja Jaekel, K Lieder, Stefan Albrecht et al. · Bone Marrow Transplantation · 2015 · 34 citations

Medicine, Hematology, Pharmacotherapy +16